PI3K/Akt/mTOR Signaling

PF-07104091 drate is a potent and selective CDK2/cyclin E1 and GSK3β inhibitor, with Kis of 1.16 and 537.81 nM, respectively.

ZINC00784494 is a specific Lipocalin-2 (LCN2) inhibitor.

CDK8-IN-12 is an orally active, potent CDK8 inhibitor with a Ki of 14 nM.

AMPK activator 12 (compound 21) is a potent AMPK activator and GDF15 inducer.

PH14 is a dual PI3K/HDAC inhibitor with IC50 values of 20.3 nM and 24.5 nM for PI3Kα and HDAC3, respectively.

PI3Kα-IN-9 (compound 27) is a selective, long-acting and oral active PI3Kα inhibitor with IC50 values of 4.4, 128, 146 and 153 nM for PI3Kα, PI3Kγ, PI3Kδ and PI3Kβ, respectively.

MS15 TFA is a potent and selective AKT PROTAC degrader.

RLY-2608 is an orally active first-in-class allosteric mutant-selective inhibitor of PI3Ka with anti-tumor activity.

BCPA is a Pin1 regulator without cytotoxicity.

Wu-5 is a USP10 inhibitor that can inhibit FLT3 and AMPK pathways, induce FLT3-ITD degradation and induce apoptosis.

SRX3177 is a triple inhibitor of CDK4/6, PI3K, and BRD4, with IC50s of 33 nM (BRD4 BD1), 89 nM (BRD4 BD2), 79 nM (PI3Kα), 83 nM (PI3Kδ), 3.18 μM (PI3Kγ), <2.5 nM (CDK4), 3.3 nM (CDK6), respectively.

MARK4 inhibitor 2 is an inhibitor of microtubule affinity-regulating kinase 4 (MARK4) with an Km of 6.3×10 7 and an IC50 of 0.82 μM.

PI3Kδ-IN-16 is a potent and selective inhibitor of PI3Kδ.

PIK5-12d is a PROTAC PIKfyve degrader (DC50: 1.48 nM).

HTH-02-006 is a NUAK2 inhibitor (IC50 = 126 nM).

ALK-IN-26 is an ALK inhibitor with IC50 value of 7.0 μM for ALK tyrosine kinase.

RMC-4998 is an orally active inhibitor targeting the active or GTP-bound state of the KRASG12C mutant.

STX-478 (compound 80) is an oral CNS-penetrant allosteric mutant-selective PI3Kα inhibitor.

TAS0612 is an orally novel inhibitor of RSK、AKT and S6K.

IBL-302 (AMU302) is an orally available dual-signaling inhibitor of PIM and PI3K/AKT/mTOR with activity against breast cancer and neuroblastoma.

Lys(CO-C3-p-I-Ph)-OMe is a pharmacokinetic modifier (PK modifier) that can improve the PK properties of PSMA ligand molecules (such as Ac-PSMA-trillium).

Lys(CO-C3-p-I-Ph)-O-tBu is a pharmacokinetic modifier (PK modifier) that can improve the PK properties of PSMA ligand molecules.

INY-05-040 is a AKT degrader that can selectively and quickly degrade all three AKT isoforms.

SKI-349 is a dual-targeted inhibitor of sphingosine kinase 1/2 (SPHK1/2) and microtubule assembly (MDA).